Hypoglycemia risk with tirzepatide monotherapy is low due to its glucose-dependent mechanism of action
Each dose increase typically produces a noticeable enhancement in appetite suppression within 3 to 5 days
Losing more than one to two pounds per week consistently also increases risk
Research has shown that even non-GLP-1RA agents have appetite-suppressing effects and can improve obesity (Li et al., 2023)
CrossRef National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation HK Chopra, Ashwani Mehta, CK Ponde, Navin C Nanda, GS Wander, Abraham Oomman, Prafulla Kerkar, SN Routray, GP Ratnaparkhi, Prashant Advani, Rituparna Shinde, Rajeev Agarwal, Ajay Mahajan, Jay Shah, Gaurav Verma, Sanjay Mittal, Dorairaj Prabhakar, D Ramesh Journal of The Association of Physicians of India.2026